|
NZ250844A
(en)
|
1993-04-07 |
1996-03-26 |
Pfizer |
Treatment of non-insulin dependant diabetes with peptides; composition
|
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
|
US5641757A
(en)
|
1994-12-21 |
1997-06-24 |
Ortho Pharmaceutical Corporation |
Stable 2-chloro-2'-deoxyadenosine formulations
|
|
CA2262647C
(en)
|
1996-08-08 |
2007-12-04 |
Amylin Pharmaceuticals, Inc. |
Methods for regulating gastrointestinal motility
|
|
UA72181C2
(uk)
|
1996-08-30 |
2005-02-15 |
Ново Нордіск А/С |
Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
|
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
PT1629849E
(pt)
|
1997-01-07 |
2013-07-09 |
Amylin Pharmaceuticals Llc |
Composições farmacêuticas que compreendem exendinas e seus agonistas
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US6723530B1
(en)
|
1997-02-05 |
2004-04-20 |
Amylin Pharmaceuticals, Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
NZ502592A
(en)
|
1997-08-08 |
2002-03-28 |
Amylin Pharmaceuticals Inc |
Exendin agonist peptides and their use in the treatment of type I and II diabetes
|
|
NZ504256A
(en)
|
1997-11-14 |
2003-01-31 |
Amylin Pharmaceuticals Inc |
Exendin 3 and 4 agonist compounds for treating diabetes
|
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
WO1999025727A2
(en)
|
1997-11-14 |
1999-05-27 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
JP4353544B2
(ja)
|
1998-01-09 |
2009-10-28 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
アミリン作動薬ペプチド用製剤
|
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
NZ506839A
(en)
|
1998-03-09 |
2003-05-30 |
Zealand Pharma As |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
JP4072319B2
(ja)
|
1998-03-13 |
2008-04-09 |
ノヴォ ノルディスク アクティーゼルスカブ |
安定化水溶性ペプチド溶液
|
|
US6998387B1
(en)
|
1998-03-19 |
2006-02-14 |
Amylin Pharmaceuticals, Inc. |
Human appetite control by glucagon-like peptide receptor binding compounds
|
|
HUP0102193A2
(hu)
|
1998-06-12 |
2001-10-28 |
Bionebraska, Inc. |
Glukagonszerű peptid-1, mely a béta-sejtek glükózra adott válaszát glükóz toleranciában sérült személyeknél javítja
|
|
DK1105460T3
(da)
|
1998-08-10 |
2010-02-08 |
Us Gov Health & Human Serv |
Differentiering af ikke-insulinproducerende celler til insulinproducerende celler med GLP-1 eller Exendin-4 og anvendelser deraf
|
|
AU765584B2
(en)
|
1998-09-17 |
2003-09-25 |
Eli Lilly And Company |
Protein formulations
|
|
US6429197B1
(en)
|
1998-10-08 |
2002-08-06 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
|
|
US7259136B2
(en)
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
|
ES2249933T3
(es)
|
1998-12-22 |
2006-04-01 |
Eli Lilly And Company |
Formulacion autoestable de peptido 1 tipo glucagon.
|
|
US20030087820A1
(en)
|
1999-01-14 |
2003-05-08 |
Young Andrew A. |
Novel exendin agonist formulations and methods of administration thereof
|
|
RU2242244C2
(ru)
|
1999-01-14 |
2004-12-20 |
Амилин Фармасьютикалз, Инк. |
Новые композиции агонистов эксендина и способы их введения
|
|
ES2343072T3
(es)
|
1999-01-14 |
2010-07-22 |
Amylin Pharmaceuticals, Inc. |
Exendina para la supresion del glucagon.
|
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
|
BR0009040A
(pt)
|
1999-03-17 |
2001-12-18 |
Novo Nordisk As |
Método para acilar um grupo amino de um peptìdeoou de uma proteìna, e, composto
|
|
CA2372214A1
(en)
|
1999-04-30 |
2000-11-09 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
WO2000069911A1
(en)
|
1999-05-17 |
2000-11-23 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US6482799B1
(en)
|
1999-05-25 |
2002-11-19 |
The Regents Of The University Of California |
Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
|
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
US6972319B1
(en)
|
1999-09-28 |
2005-12-06 |
Bayer Pharmaceuticals Corporation |
Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
|
|
GB9930882D0
(en)
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
|
ATE275967T1
(de)
|
2000-01-10 |
2004-10-15 |
Amylin Pharmaceuticals Inc |
Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie
|
|
CN1487836A
(zh)
|
2000-03-14 |
2004-04-07 |
埃米林药品公司 |
胰高糖素样肽1(7-36)对胃窦幽门十二指肠能动性的影响
|
|
US20020061838A1
(en)
|
2000-05-17 |
2002-05-23 |
Barton Holmquist |
Peptide pharmaceutical formulations
|
|
CN103356996A
(zh)
|
2000-05-19 |
2013-10-23 |
埃米林药品公司 |
Glp-1用于制备治疗急性冠脉综合征的药物的用途
|
|
EP1317412A1
(en)
|
2000-08-18 |
2003-06-11 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US7507714B2
(en)
|
2000-09-27 |
2009-03-24 |
Bayer Corporation |
Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
|
|
WO2002034285A2
(en)
|
2000-10-20 |
2002-05-02 |
Coolidge Thomas R |
Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
|
|
IL155812A0
(en)
|
2000-12-07 |
2003-12-23 |
Lilly Co Eli |
Glp-1 fusion proteins
|
|
WO2002047716A2
(en)
|
2000-12-13 |
2002-06-20 |
Eli Lilly And Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
|
GB2371227A
(en)
|
2001-01-10 |
2002-07-24 |
Grandis Biotech Gmbh |
Crystallisation - resistant aqueous growth hormone formulations
|
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
|
CN1162446C
(zh)
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
|
EP1542712A2
(en)
|
2001-06-01 |
2005-06-22 |
Eli Lilly And Company |
Glp-1 formulations with protracted time action
|
|
JP5562510B2
(ja)
|
2001-06-28 |
2014-07-30 |
ノヴォ ノルディスク アー／エス |
修飾ｇｌｐ−１の安定な処方剤
|
|
IL159857A0
(en)
|
2001-07-16 |
2004-06-20 |
Hk Pharmaceuticals Inc |
Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
|
|
EP2275117B1
(en)
|
2001-07-31 |
2016-10-26 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
GLP-1, exendin-4, peptide analogs and uses thereof
|
|
JP2005508895A
(ja)
|
2001-08-28 |
2005-04-07 |
イーライ・リリー・アンド・カンパニー |
Ｇｌｐ−１および基礎インスリンの予備混合物
|
|
US7179788B2
(en)
|
2001-10-19 |
2007-02-20 |
Eli Lilly And Company |
Biphasic mixtures of GLP-1 and insulin
|
|
EP2277910A1
(en)
|
2001-12-21 |
2011-01-26 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
EP1463752A4
(en)
|
2001-12-21 |
2005-07-13 |
Human Genome Sciences Inc |
ALBUMIN FUSION PROTEINS
|
|
US7105489B2
(en)
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
|
RU2332229C2
(ru)
|
2002-02-20 |
2008-08-27 |
Эмисфире Текнолоджис Инк. |
Способ введения молекул glp-1
|
|
PT1478394E
(pt)
|
2002-02-27 |
2008-10-08 |
Immunex Corp |
Composição estabilizada compreendendo tnfr - fc e arginina
|
|
EP1502102B1
(en)
|
2002-03-11 |
2009-01-14 |
caprotec bioanalytics GmbH |
Compounds and methods for analyzing the proteome
|
|
US7141240B2
(en)
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
|
JP2005535569A
(ja)
|
2002-04-04 |
2005-11-24 |
ノボ・ノルデイスク・エー／エス |
Ｇｌｐ−１アゴニスト及び心臓血管合併症
|
|
IL164266A0
(en)
|
2002-04-10 |
2005-12-18 |
Lilly Co Eli |
Treatment of gastroparesis
|
|
US6861236B2
(en)
|
2002-05-24 |
2005-03-01 |
Applied Nanosystems B.V. |
Export and modification of (poly)peptides in the lantibiotic way
|
|
EP1515749B1
(en)
|
2002-06-14 |
2012-08-15 |
Novo Nordisk A/S |
Combined use of a modulator of cd3 and a glp-1 compound
|
|
US20040037826A1
(en)
|
2002-06-14 |
2004-02-26 |
Michelsen Birgitte Koch |
Combined use of a modulator of CD3 and a GLP-1 compound
|
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
|
DK1525219T3
(da)
|
2002-07-04 |
2009-09-07 |
Zealand Pharma As |
GLP-1 og fremgangsm der til behandling af diabetes
|
|
US20070065469A1
(en)
|
2002-07-09 |
2007-03-22 |
Michael Betz |
Liquid formulations with high concentration of human growth hormone (high) comprising glycine
|
|
MXPA05000412A
(es)
|
2002-07-09 |
2005-07-22 |
Sandoz Ag |
Formulacioneks liquidas con una alta concentracion de hormona de crecimiento humana (hgh) que comprenden glicina.
|
|
US20040038865A1
(en)
|
2002-08-01 |
2004-02-26 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
|
US20080260838A1
(en)
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
|
AU2003257156B2
(en)
|
2002-08-01 |
2007-08-30 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
KR101150449B1
(ko)
|
2002-08-21 |
2012-06-01 |
베링거 잉겔하임 파르마 게엠베하 운트 코 카게 |
8-［3-아미노-피페리딘-1-일］-크산틴, 이의 제조방법 및 이를 포함하는 약제학적 조성물
|
|
AU2003268621B2
(en)
|
2002-10-02 |
2009-01-15 |
Zealand Pharma A/S |
Stabilized exendin-4 compounds
|
|
PT1583541E
(pt)
|
2002-11-20 |
2011-04-06 |
Neuronova Ab |
Compostos e métodos para o aumento da neurogénese
|
|
US6969702B2
(en)
|
2002-11-20 |
2005-11-29 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
|
US20050209142A1
(en)
|
2002-11-20 |
2005-09-22 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
|
US20040209803A1
(en)
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
|
JP2006514035A
(ja)
|
2002-12-17 |
2006-04-27 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
心不整脈の予防および治療
|
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
|
CA2843439A1
(en)
|
2003-04-08 |
2004-10-21 |
Yeda Research And Development Co. Ltd |
Reversible pegylated drugs
|
|
WO2004089985A1
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Stable pharmaceutical compositions
|
|
WO2004103390A2
(en)
|
2003-05-15 |
2004-12-02 |
Trustees Of Tufts College |
Stable analogs of peptide and polypeptide therapeutics
|
|
US7947261B2
(en)
|
2003-05-23 |
2011-05-24 |
Nektar Therapeutics |
Conjugates formed from polymer derivatives having particular atom arrangements
|
|
CN1747748B
(zh)
|
2003-05-23 |
2011-01-19 |
尼克塔治疗公司 |
具有特定原子排列的聚合物衍生物
|
|
WO2005000222A2
(en)
|
2003-05-30 |
2005-01-06 |
Amylin Pharmaceuticals, Inc. |
Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
|
JP2007524592A
(ja)
|
2003-06-03 |
2007-08-30 |
ノボ・ノルデイスク・エー／エス |
安定化された薬学的ペプチド組成物
|
|
ATE541582T1
(de)
|
2003-06-03 |
2012-02-15 |
Novo Nordisk As |
Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
|
|
EP1633390B1
(en)
|
2003-06-03 |
2012-01-18 |
Novo Nordisk A/S |
Stabilized pharmaceutical glp-1 peptide compositions
|
|
ATE529126T1
(de)
|
2003-06-03 |
2011-11-15 |
Novo Nordisk As |
Stabilisierte pharmazeutische peptid zusammensetzungen
|
|
US8921311B2
(en)
|
2003-08-01 |
2014-12-30 |
Mannkind Corporation |
Method for treating hyperglycemia
|
|
EP2264065B1
(en)
|
2003-08-05 |
2017-03-08 |
Novo Nordisk A/S |
Novel insulin derivatives
|
|
KR20060106812A
(ko)
|
2003-08-21 |
2006-10-12 |
노보 노르디스크 에이/에스 |
라세미화 아미노산을 포함하는 폴리펩티드의 분리
|
|
EP1663295A2
(en)
|
2003-09-01 |
2006-06-07 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
US20060247167A1
(en)
|
2003-09-01 |
2006-11-02 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
TW200522976A
(en)
|
2003-09-19 |
2005-07-16 |
Novo Nordisk As |
Novel plasma protein affinity tags
|
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
|
WO2005046716A1
(en)
|
2003-11-13 |
2005-05-26 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia
|
|
US20050106214A1
(en)
|
2003-11-14 |
2005-05-19 |
Guohua Chen |
Excipients in drug delivery vehicles
|
|
US20050281879A1
(en)
|
2003-11-14 |
2005-12-22 |
Guohua Chen |
Excipients in drug delivery vehicles
|
|
EP1750752A2
(en)
|
2003-11-20 |
2007-02-14 |
Neuronova AB |
Compounds and methods for increasing neurogenesis
|
|
CN1882356B
(zh)
|
2003-11-20 |
2015-02-25 |
诺沃挪第克公司 |
对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
|
|
CN1902226A
(zh)
|
2003-12-03 |
2007-01-24 |
诺和诺德公司 |
单链胰岛素
|
|
US9539337B2
(en)
|
2003-12-10 |
2017-01-10 |
Nektar Therapeutics |
Compositions comprising two different populations of polymer-active agent conjugates
|
|
US20060210614A1
(en)
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
|
US20050143303A1
(en)
|
2003-12-26 |
2005-06-30 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of glucose-regulating peptides
|
|
CN1938334A
(zh)
*
|
2004-01-30 |
2007-03-28 |
瓦拉塔药品公司 |
Glp－1激动剂和胃泌素化合物的联合使用
|
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
EP2417980A1
(en)
|
2004-02-11 |
2012-02-15 |
Amylin Pharmaceuticals Inc. |
Hybrid polypeptides with selectable properties
|
|
US8603969B2
(en)
|
2004-02-11 |
2013-12-10 |
Amylin Pharmaceuticals, Llc |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
|
WO2006083254A1
(en)
|
2004-02-11 |
2006-08-10 |
Amylin Pharmaceuticals, Inc. |
Amylin family peptides and methods for making and using them
|
|
US7399744B2
(en)
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
|
US20060110423A1
(en)
|
2004-04-15 |
2006-05-25 |
Wright Steven G |
Polymer-based sustained release device
|
|
US7456254B2
(en)
|
2004-04-15 |
2008-11-25 |
Alkermes, Inc. |
Polymer-based sustained release device
|
|
EA200601904A1
(ru)
|
2004-04-15 |
2007-02-27 |
Алкермес, Инк. |
Система отсроченного высвобождения лекарственного средства на основе полимеров
|
|
WO2005117584A2
(en)
|
2004-05-28 |
2005-12-15 |
Amylin Pharmaceuticals, Inc |
Improved transmucosal delivery of peptides and proteins
|
|
US20090069226A1
(en)
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
|
US8410047B2
(en)
|
2004-06-11 |
2013-04-02 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using GLP-1 agonists
|
|
CN101027318B
(zh)
|
2004-07-19 |
2016-05-25 |
比奥孔有限公司 |
胰岛素-低聚物共轭物，制剂及其用途
|
|
BRPI0512396A
(pt)
|
2004-07-21 |
2008-03-11 |
Ambrx Inc |
polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
|
|
CA2575756A1
(en)
|
2004-08-03 |
2006-02-16 |
Biorexis Technology, Inc. |
Combination therapy using transferrin fusion proteins comprising glp-1
|
|
WO2006017888A1
(en)
|
2004-08-16 |
2006-02-23 |
Water Un Limited |
Apparatus and method for cooling of air
|
|
JP4965446B2
(ja)
|
2004-08-31 |
2012-07-04 |
ノヴォ ノルディスク アー／エス |
ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス（ヒドロキシメチル）アミノメタンの使用
|
|
DE102004043153B4
(de)
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
|
TW200612991A
(en)
|
2004-09-07 |
2006-05-01 |
Chugai Pharmaceutical Co Ltd |
Process for producing water-soluble hyaluronic acid modification
|
|
EP1791554A2
(en)
|
2004-09-17 |
2007-06-06 |
Novo Nordisk A/S |
Pharmaceutical compositions containing insulin and insulinotropic peptide
|
|
NZ554426A
(en)
|
2004-10-01 |
2010-05-28 |
Ramscor Inc |
Conveniently implantable sustained release drug compositions comprising at least one non-polymeric excipient
|
|
US8030273B2
(en)
|
2004-10-07 |
2011-10-04 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
|
US7595294B2
(en)
|
2004-10-08 |
2009-09-29 |
Transition Therapeutics, Inc. |
Vasoactive intestinal polypeptide pharmaceuticals
|
|
WO2006044531A2
(en)
|
2004-10-13 |
2006-04-27 |
Isis Parmaceuticals, Inc. |
Antisense modulation of ptp1b expression
|
|
US7442682B2
(en)
|
2004-10-19 |
2008-10-28 |
Nitto Denko Corporation |
Transepithelial delivery of peptides with incretin hormone activities
|
|
WO2006051103A2
(en)
|
2004-11-12 |
2006-05-18 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
BRPI0517341A
(pt)
|
2004-11-12 |
2008-10-07 |
Novo Nordisk As |
composição farmacêutica estável em prateleira, métodos para a preparação de uma composição farmacêutica, para o tratamento de hiperglicemia, para o tratamento de obesidade, deficiência de célula beta, igt ou dislipidemia, para a preparação de uma solução estável de um composto glp-1, para a preparação de um composto glp-1 estável e para a preparação de uma composição farmacêutica estável em prateleira de um composto glp-1, solução estável de um composto glp-1, e, uso de uma solução estável de um composto glp-1
|
|
CN101056650A
(zh)
|
2004-11-12 |
2007-10-17 |
诺和诺德公司 |
促胰岛素肽的稳定制剂
|
|
CN101128487B
(zh)
|
2004-12-02 |
2012-10-10 |
杜门蒂斯有限公司 |
靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
|
|
CA2836267C
(en)
|
2004-12-13 |
2016-06-21 |
Amylin Pharmaceuticals, Llc |
Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
|
|
US7851565B2
(en)
|
2004-12-21 |
2010-12-14 |
Nektar Therapeutics |
Stabilized polymeric thiol reagents
|
|
PL1831252T3
(pl)
|
2004-12-22 |
2009-11-30 |
Lilly Co Eli |
Preparaty białka fuzyjnego analogu GLP-1
|
|
US20070021336A1
(en)
|
2004-12-24 |
2007-01-25 |
Christen Anderson |
Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosis
|
|
JP4785206B2
(ja)
|
2005-01-14 |
2011-10-05 |
ウクスィ・グランドチャンプ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド |
修飾されたエキセンディン（Ｅｘｅｎｄｉｎｓ）及びその使用
|
|
US8716221B2
(en)
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
|
WO2006082588A2
(en)
|
2005-02-07 |
2006-08-10 |
Pharmalight Inc. |
Method and device for ophthalmic administration of active pharmaceutical ingredients
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
BRPI0606992A2
(pt)
|
2005-02-11 |
2009-07-28 |
Amylin Pharmaceuticals Inc |
análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
|
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
|
WO2006110887A2
(en)
|
2005-04-11 |
2006-10-19 |
Amylin Pharmaceuticals, Inc |
Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
|
|
CN101163514B
(zh)
|
2005-04-24 |
2012-01-25 |
诺和诺德公司 |
注射装置
|
|
JP5235661B2
(ja)
|
2005-05-25 |
2013-07-10 |
ノボ・ノルデイスク・エー／エス |
安定化ポリペプチド製剤
|
|
KR20080026117A
(ko)
|
2005-05-26 |
2008-03-24 |
브리스톨-마이어스 스큅 컴퍼니 |
Ｎ-말단 개질된 ｇｌｐ-1 수용체 조절제
|
|
CA2609810C
(en)
|
2005-06-06 |
2012-05-22 |
Camurus Ab |
Glp-1 analogue formulations
|
|
JP2008543816A
(ja)
|
2005-06-13 |
2008-12-04 |
インペリアル イノベーションズ リミテッド |
新規化合物および該化合物が摂食行動に及ぼす効果
|
|
GB0511986D0
(en)
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
|
RS53968B1
(sr)
|
2005-06-16 |
2015-08-31 |
Nektar Therapeutics |
Konjugati koji imaju spojnicu koja može da se razgradi i polimerni reagensi koji su korisni za pripremu takvih konjugata
|
|
JP2009503111A
(ja)
|
2005-08-04 |
2009-01-29 |
ネクター セラピューティックス エイエル，コーポレイション |
Ｇ−ｃｓｆ部分および重合体の複合体
|
|
CA2658678A1
(en)
|
2005-08-06 |
2007-02-15 |
Gerald J. Prud'homme |
Composition and method for prevention and treatment of type i diabetes
|
|
EP2330124B1
(en)
|
2005-08-11 |
2015-02-25 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
|
LT2347762T
(lt)
|
2005-08-19 |
2019-08-26 |
Amylin Pharmaceuticals, Llc |
Eksendinas, skirtas diabeto gydymui ir kūno svorio mažinimui
|
|
KR101486397B1
(ko)
|
2005-09-14 |
2015-01-28 |
맨카인드 코포레이션 |
활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
|
|
JP5072848B2
(ja)
|
2005-09-20 |
2012-11-14 |
ノバルティス アーゲー |
低血糖イベントを低減するためのｄｐｐ−ｉｖ阻害剤の使用
|
|
US8759290B2
(en)
|
2005-10-18 |
2014-06-24 |
Biocon Limited |
Oral glucagon-like peptide conjugates for metabolic diseases
|
|
US7687608B2
(en)
|
2005-10-19 |
2010-03-30 |
Smartcells, Inc. |
Methods for reducing the mitogenicity of lectin compositions
|
|
CA2913805A1
(en)
|
2005-11-07 |
2007-05-18 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
|
US8039432B2
(en)
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
|
EP1968607B1
(en)
|
2005-12-02 |
2014-01-15 |
Nabil Habib Lab |
Treatment of cancer and other diseases
|
|
MX2008007075A
(es)
|
2005-12-02 |
2008-11-12 |
Mdrna Inc |
Formulacion farmaceutica para incrementar la permeabilidad epitelial por peptido regulador de glucosa.
|
|
WO2007067964A2
(en)
|
2005-12-08 |
2007-06-14 |
Nastech Pharmaceutical Company Inc. |
Mucosal delivery of stabilized formulations of exendin
|
|
WO2007075534A2
(en)
|
2005-12-16 |
2007-07-05 |
Nektar Therapeutics Al, Corporation |
Polymer conjugates of glp-1
|
|
ES2779992T3
(es)
|
2005-12-20 |
2020-08-21 |
Univ Duke |
Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
|
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
SI1984009T1
(sl)
|
2006-01-18 |
2013-02-28 |
Qps, Llc |
Farmacevtski sestavki z izboljĺ ano stabilnostjo
|
|
KR20080098504A
(ko)
|
2006-02-03 |
2008-11-10 |
메디뮨 엘엘씨 |
단백질 제제
|
|
US7704953B2
(en)
|
2006-02-17 |
2010-04-27 |
Mdrna, Inc. |
Phage displayed cell binding peptides
|
|
CN101432025B
(zh)
|
2006-03-21 |
2012-04-04 |
安米林药品公司 |
肽-肽酶抑制剂结合物及其使用方法
|
|
NZ571862A
(en)
|
2006-04-13 |
2011-10-28 |
Ipsen Pharma Sas |
Pharmaceutical composition comprising HGLP-1, a zinc divalent metal ion and a solvent
|
|
RU2409349C2
(ru)
|
2006-04-14 |
2011-01-20 |
Маннкайнд Корпорейшн |
Фармацевтические композиции, содержащие глюкагонподобный пептид(glp-1)
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
EP2029160A2
(en)
|
2006-05-12 |
2009-03-04 |
Amylin Pharmaceuticals, Inc. |
Methods to restore glycemic control
|
|
EP2021014A1
(en)
|
2006-05-26 |
2009-02-11 |
Brystol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
|
CN101454342A
(zh)
|
2006-05-26 |
2009-06-10 |
安米林药品公司 |
用于治疗充血性心力衰竭的组合物及方法
|
|
ES2401856T3
(es)
|
2006-06-21 |
2013-04-25 |
Biocon Limited |
Un método para producir un polipéptido biológicamente activo que tiene actividad insulinotrópica
|
|
EP2051697A2
(en)
|
2006-07-05 |
2009-04-29 |
Foamix Ltd. |
Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof
|
|
CN101511868B
(zh)
|
2006-07-24 |
2013-03-06 |
比奥雷克西斯制药公司 |
毒蜥外泌肽融合蛋白
|
|
US7928186B2
(en)
|
2006-08-02 |
2011-04-19 |
Phoenix Pharmaceuticals, Inc. |
Cell permeable bioactive peptide conjugates
|
|
AU2007281433A1
(en)
|
2006-08-04 |
2008-02-07 |
Nastech Pharmaceutical Company Inc. |
Compositions for intranasal delivery of human insulin and uses thereof
|
|
JP5048773B2
(ja)
|
2006-08-09 |
2012-10-17 |
インターシア セラピューティクス，インコーポレイティド |
浸透圧式デリバリーシステム及びピストンアセンブリー
|
|
AU2007284365A1
(en)
|
2006-08-17 |
2008-02-21 |
Amylin Pharmaceuticals, Inc. |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
US20090318353A1
(en)
*
|
2006-08-25 |
2009-12-24 |
Novo Nordisk A/S |
Acylated Exendin-4 Compounds
|
|
CN101125207B
(zh)
|
2006-11-14 |
2012-09-05 |
上海华谊生物技术有限公司 |
带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
|
|
JP2010512399A
(ja)
|
2006-12-12 |
2010-04-22 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
医薬製剤及びその調製方法
|
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
|
US20090098130A1
(en)
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
|
CN101663317A
(zh)
*
|
2007-01-05 |
2010-03-03 |
CovX科技爱尔兰有限公司 |
胰高血糖素样蛋白-1受体glp-1r激动剂化合物
|
|
WO2008086086A2
(en)
|
2007-01-05 |
2008-07-17 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
|
|
RU2432361C2
(ru)
|
2007-01-05 |
2011-10-27 |
КовЭкс Текнолоджиз Айэлэнд Лимитед |
Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r)
|
|
WO2008098212A2
(en)
|
2007-02-08 |
2008-08-14 |
Diobex, Inc. |
Extended release formulations of glucagon and other peptides and proteins
|
|
MX2009008241A
(es)
|
2007-02-15 |
2009-10-08 |
Univ Indiana Res & Tech Corp |
Co-agonistas de receptor de glucagon/glp-1.
|
|
WO2008130066A1
(en)
|
2007-04-20 |
2008-10-30 |
Kang Choon Lee |
Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
|
|
NZ580447A
(en)
|
2007-04-23 |
2011-06-30 |
Intarcia Therapeutics Inc |
Suspension formulations of insulinotropic peptides and uses thereof
|
|
US8236760B2
(en)
|
2007-04-27 |
2012-08-07 |
Cedars-Sinsai Medical Center |
Use of GLP-1 receptor agonists for the treatment of short bowel syndrome
|
|
US7829664B2
(en)
|
2007-06-01 |
2010-11-09 |
Boehringer Ingelheim International Gmbh |
Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (GLP-1), human cells comprising said construct and insulin-producing constructs, and methods of use thereof
|
|
US9353170B2
(en)
|
2007-06-08 |
2016-05-31 |
Sanofi-Aventis Deutschland Gmbh |
Long-acting transient polymer conjugates of exendin
|
|
EP2158214B1
(en)
|
2007-06-15 |
2011-08-17 |
Zealand Pharma A/S |
Glucagon analogues
|
|
EP2175834B8
(en)
|
2007-07-10 |
2012-08-22 |
Eli Lilly And Company |
Glp-1-fc fusion protein formulation
|
|
CA2693504A1
(en)
|
2007-08-03 |
2009-02-12 |
Eli Lilly And Company |
Treatment for obesity
|
|
CN101366692A
(zh)
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
|
MX2010002264A
(es)
|
2007-08-30 |
2010-08-02 |
Curedm Inc |
Composiciones y métodos para utilizar péptidos proislet y sus analogos.
|
|
US20100261637A1
(en)
|
2007-09-05 |
2010-10-14 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
US20100256056A1
(en)
|
2007-09-07 |
2010-10-07 |
Zheng Xin Dong |
Analogues of exendin-4 and exendin-3
|
|
KR101736502B1
(ko)
|
2007-10-24 |
2017-05-16 |
맨카인드 코포레이션 |
Ｇｌｐ-1에 의한 유해 효과의 예방 방법
|
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
|
JP5813323B2
(ja)
|
2007-10-24 |
2015-11-17 |
マンカインド コーポレイション |
活性薬剤の送達方法
|
|
US8981047B2
(en)
|
2007-10-30 |
2015-03-17 |
Indiana University Research And Technology Corporation |
Glucagon antagonists
|
|
ES2558155T3
(es)
|
2007-10-30 |
2016-02-02 |
Indiana University Research And Technology Corporation |
Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
|
|
DK2597103T3
(en)
|
2007-11-16 |
2017-02-13 |
Novo Nordisk As |
Stable pharmaceutical compositions comprising liraglutide and degludec
|
|
WO2009067268A1
(en)
|
2007-11-23 |
2009-05-28 |
Michael Rothkopf |
Methods of enhancing diabetes resolution
|
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
CN102026666B
(zh)
|
2007-12-11 |
2013-10-16 |
常山凯捷健生物药物研发（河北）有限公司 |
促胰岛素肽缀合物制剂
|
|
DK2229407T3
(en)
|
2008-01-09 |
2017-02-27 |
Sanofi Aventis Deutschland |
NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE
|
|
CN101983066B
(zh)
|
2008-01-30 |
2016-06-29 |
印第安那大学科技研究公司 |
基于酯的胰岛素前药
|
|
RS58948B1
(sr)
|
2008-02-01 |
2019-08-30 |
Ascendis Pharma As |
Prolek koji sadrži linker koji se može sam odcepiti
|
|
MX2010008654A
(es)
|
2008-02-06 |
2010-10-06 |
Biocon Ltd |
Medios de fermentacion y procedimientos para los mismos.
|
|
WO2009114959A1
(zh)
|
2008-03-20 |
2009-09-24 |
中国人民解放军军事医学科学院毒物药物研究所 |
可注射用缓释药物制剂及其制备方法
|
|
EP2282763B1
(en)
|
2008-04-07 |
2013-12-11 |
National Institute Of Immunology |
Process for preparing supramolecular calcitonin assemblies (SCA)
|
|
KR20110007614A
(ko)
|
2008-05-07 |
2011-01-24 |
메리온 리서치 Ⅲ 리미티드 |
ＧｎＲＨ 관련 화합물의 조성물 및 제조 방법
|
|
US20110263496A1
(en)
|
2008-05-21 |
2011-10-27 |
Amylin Pharmaceuticals, Inc. |
Exendins to lower cholesterol and triglycerides
|
|
EP2288918A1
(en)
|
2008-05-23 |
2011-03-02 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist bioassays
|
|
US9358352B2
(en)
|
2008-06-13 |
2016-06-07 |
Mannkind Corporation |
Dry powder drug delivery system and methods
|
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
|
RU2608439C2
(ru)
|
2008-06-13 |
2017-01-18 |
Маннкайнд Корпорейшн |
Ингалятор для сухого порошка и система для доставки лекарственных средств
|
|
KR20110039230A
(ko)
|
2008-06-17 |
2011-04-15 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
|
|
BRPI0914889A2
(pt)
|
2008-06-17 |
2015-11-24 |
Otsuka Chemical Co Ltd |
peptídeo glp-1 adicionado de cadeia oligossacarídica
|
|
PA8830501A1
(es)
|
2008-06-17 |
2010-07-27 |
Univ Indiana Res & Tech Corp |
Co-agonistas del receptor de glucagon/glp-1
|
|
BRPI0915282A2
(pt)
|
2008-06-17 |
2017-02-07 |
Univ Indiana Res & Tech Corp |
agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
|
|
CA2726894A1
(en)
|
2008-06-27 |
2009-12-30 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
|
EP2303247A4
(en)
|
2008-07-21 |
2012-08-01 |
Syneron Medical Ltd |
TRANSDERMALES SYSTEM FOR THE EXTENDED RELEASE OF INCRETINS AND INCRETIN MIMETIC PEPTIDES
|
|
WO2010013012A2
(en)
|
2008-08-01 |
2010-02-04 |
Lund University Bioscience Ab |
Novel polypeptides and uses thereof
|
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
CN103736082A
(zh)
|
2008-10-17 |
2014-04-23 |
赛诺菲-安万特德国有限公司 |
胰岛素和glp-1激动剂的组合
|
|
WO2010068735A1
(en)
|
2008-12-10 |
2010-06-17 |
Glaxosmithkline Llc. |
Pharmaceutical compositions
|
|
US8685919B2
(en)
|
2008-12-15 |
2014-04-01 |
Zealand Pharma A/S |
Glucagon analogues
|
|
US8642541B2
(en)
|
2008-12-15 |
2014-02-04 |
Zealand Pharma A/S |
Glucagon analogues
|
|
AU2008365556A1
(en)
|
2008-12-15 |
2011-07-21 |
Zealand Pharma A/S |
Glucagon analogues
|
|
EA020596B1
(ru)
|
2008-12-15 |
2014-12-30 |
Зилэнд Фарма А/С |
Аналоги глюкагона
|
|
SG172291A1
(en)
|
2008-12-19 |
2011-07-28 |
Univ Indiana Res & Tech Corp |
Amide based glucagon superfamily peptide prodrugs
|
|
CN101538323B
(zh)
|
2009-01-13 |
2012-05-09 |
深圳翰宇药业股份有限公司 |
一种纯化艾塞那肽的方法
|
|
DE102009006602A1
(de)
|
2009-01-29 |
2010-08-05 |
Bayer Schering Pharma Aktiengesellschaft |
Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
|
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
|
EP2403490B1
(en)
|
2009-03-04 |
2019-08-07 |
MannKind Corporation |
An improved dry powder drug delivery system
|
|
CA2753939A1
(en)
|
2009-03-05 |
2010-09-10 |
Sanofi-Aventis Deutschland Gmbh |
Drug delivery device with retractable needle
|
|
EP2413955A4
(en)
|
2009-04-01 |
2012-12-26 |
Amylin Pharmaceuticals Inc |
N-TERMINAL CONFORMATION RESTRICTED GLP-1 RECEPTOR AGONIST COMPOUNDS
|
|
WO2010118034A2
(en)
|
2009-04-06 |
2010-10-14 |
Board Of Regents, The University Of Texas System |
Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
|
|
CA2758445C
(en)
|
2009-04-22 |
2016-02-16 |
Alteogen, Inc. |
In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
|
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
|
CN101559041B
(zh)
|
2009-05-19 |
2014-01-15 |
中国科学院过程工程研究所 |
粒径均一的多肽药物缓释微球或微囊制剂及制备方法
|
|
CA2760760A1
(en)
|
2009-05-20 |
2010-11-25 |
Sanofi-Aventis Deutschland Gmbh |
A bung for drug containing cartridges in drug delivery devices
|
|
EP3189868B1
(en)
|
2009-05-20 |
2024-10-23 |
Sanofi-Aventis Deutschland GmbH |
A bung for drug containing cartridges in drug delivery devices comprising an electronic coding feature
|
|
US20120231022A1
(en)
|
2009-05-28 |
2012-09-13 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist compounds for sleep enhancement
|
|
EP2440235A1
(en)
|
2009-06-11 |
2012-04-18 |
Novo Nordisk A/S |
Glp-1 and fgf21 combinations for treatment of diabetes type 2
|
|
PE20120914A1
(es)
|
2009-06-16 |
2012-08-22 |
Univ Indiana Res & Tech Corp |
Compuestos glucagon activo de receptor de gip
|
|
JP5932642B2
(ja)
|
2009-07-02 |
2016-06-08 |
アンジオケム インコーポレーテッド |
多量体ペプチドコンジュゲートおよびその使用
|
|
DK2454282T3
(en)
|
2009-07-13 |
2015-05-04 |
Zealand Pharma As |
acetylated glucagonanaloger
|
|
CN101601646B
(zh)
|
2009-07-22 |
2011-03-23 |
南京凯瑞尔纳米生物技术有限公司 |
治疗糖尿病的鼻腔滴剂及其制备方法
|
|
WO2011011675A1
(en)
|
2009-07-23 |
2011-01-27 |
Zelos Therapeutics, Inc. |
Pharmaceutically acceptable formulations/compositions for peptidyl drugs
|
|
EP2459228B1
(en)
|
2009-07-31 |
2020-03-04 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an insulin linker conjugate
|
|
WO2011017835A1
(en)
|
2009-08-11 |
2011-02-17 |
Nanjing University |
Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
|
|
CN101993485B
(zh)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
|
US20120148586A1
(en)
|
2009-08-27 |
2012-06-14 |
Joyce Ching Tsu Chou |
Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
|
|
KR20120092611A
(ko)
|
2009-09-30 |
2012-08-21 |
글락소 그룹 리미티드 |
연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
|
|
US20110097386A1
(en)
|
2009-10-22 |
2011-04-28 |
Biodel, Inc. |
Stabilized glucagon solutions
|
|
US9610329B2
(en)
|
2009-10-22 |
2017-04-04 |
Albireo Pharma, Inc. |
Stabilized glucagon solutions
|
|
DK2490708T3
(da)
|
2009-10-22 |
2013-04-15 |
Biodel Inc |
Stabiliserede glucagon-opløsninger
|
|
AU2010312655A1
(en)
|
2009-10-30 |
2012-05-03 |
Glytech, Inc. |
Glycosylated form of antigenic GLP-1 analogue
|
|
JP5696156B2
(ja)
|
2009-11-02 |
2015-04-08 |
ファイザー・インク |
ジオキサ−ビシクロ［３．２．１］オクタン−２，３，４−トリオール誘導体
|
|
US20120294855A1
(en)
|
2009-11-03 |
2012-11-22 |
Eli Lilly & Company |
Glp-1 receptor agonist compounds for obstructive sleep apnea
|
|
CN102711804B
(zh)
|
2009-11-13 |
2015-09-16 |
赛诺菲-安万特德国有限公司 |
包含glp-1激动剂和甲硫氨酸的药物组合物
|
|
AU2010317995B2
(en)
|
2009-11-13 |
2014-04-17 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
|
|
KR20120092714A
(ko)
|
2009-12-15 |
2012-08-21 |
메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 |
비만 및 다른 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온 및 복합제
|
|
EP2512470B1
(en)
|
2009-12-15 |
2016-11-30 |
Octeta Therapeutics, LLC |
Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
|
|
DK2513070T3
(en)
|
2009-12-15 |
2018-01-22 |
Cirius Therapeutics Inc |
PPAR-sparing thiazolidinedione salts for the treatment of metabolic disorders
|
|
AU2010340058A1
(en)
|
2009-12-15 |
2012-06-21 |
Metabolic Solutions Development Company, Llc |
PPAR-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases
|
|
JP6006118B2
(ja)
|
2009-12-16 |
2016-10-12 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１アナログ及び誘導体
|
|
US8703701B2
(en)
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
|
WO2011075623A1
(en)
|
2009-12-18 |
2011-06-23 |
Latitude Pharmaceuticals, Inc. |
One - phase gel compos ition compri s ing phos pholi pids
|
|
CN101798588B
(zh)
*
|
2009-12-21 |
2015-09-09 |
上海仁会生物制药股份有限公司 |
Glp-1受体激动剂生物学活性测定方法
|
|
JO2976B1
(en)
|
2009-12-22 |
2016-03-15 |
ايلي ليلي اند كومباني |
Axentomodulin polypeptide
|
|
AR079344A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
|
|
MX342409B
(es)
|
2010-01-20 |
2016-09-28 |
Zealand Pharma As |
Tratamiento de enfermedades cardiacas.
|
|
RU2012136450A
(ru)
*
|
2010-01-27 |
2014-03-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
|
|
AU2011209472B2
(en)
|
2010-02-01 |
2014-07-24 |
Sanofi-Aventis Deutschland Gmbh |
Cartridge holder, drug delivery device and method for securing a cartridge in a cartridge holder
|
|
WO2011109784A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Formulation of insulinotropic peptide conjugates
|
|
EP2550040A4
(en)
|
2010-03-24 |
2014-03-26 |
Shifamed Holdings Llc |
DISSOCIATION OF INTRAVASCULAR TISSUE
|
|
CN102918055B
(zh)
|
2010-03-26 |
2017-03-29 |
诺沃—诺迪斯克有限公司 |
新的胰高血糖素类似物
|
|
AR080592A1
(es)
*
|
2010-03-26 |
2012-04-18 |
Lilly Co Eli |
Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
|
|
CN103079587B
(zh)
|
2010-05-13 |
2016-05-11 |
印第安纳大学研究及科技有限公司 |
呈现核激素受体活性的胰高血糖素超家族肽
|
|
EP2568993A4
(en)
|
2010-05-13 |
2014-02-19 |
Univ Indiana Res & Tech Corp |
GLUCAGON SUPERFAMILY PEPTIDES WITH G-PROTEIN-COUPLED RECEPTOR ACTIVITY
|
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
JP2013529080A
(ja)
|
2010-05-20 |
2013-07-18 |
グラクソ グループ リミテッド |
改良された抗血清アルブミン結合変異体
|
|
US8263554B2
(en)
|
2010-06-09 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
Methods of using GLP-1 receptor agonists to treat pancreatitis
|
|
CN101891823B
(zh)
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
|
US8636711B2
(en)
|
2010-06-14 |
2014-01-28 |
Legacy Emanuel Hospital & Health Center |
Stabilized glucagon solutions and uses therefor
|
|
AR081975A1
(es)
|
2010-06-23 |
2012-10-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
US9234023B2
(en)
|
2010-06-24 |
2016-01-12 |
Biousian Biosystems, Inc. |
Glucagon-like peptide-1 glycopeptides
|
|
WO2011163012A2
(en)
|
2010-06-24 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
|
WO2011163473A1
(en)
|
2010-06-25 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
|
|
US20120046225A1
(en)
|
2010-07-19 |
2012-02-23 |
The Regents Of The University Of Colorado, A Body Corporate |
Stable glucagon formulations for the treatment of hypoglycemia
|
|
WO2012012352A2
(en)
|
2010-07-19 |
2012-01-26 |
Amidebio, Llc |
Modified peptides and proteins
|
|
EA201390182A1
(ru)
|
2010-07-28 |
2014-01-30 |
АМИЛИН ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Соединения-агонисты рецептора glp-1, содержащие стабилизированные области
|
|
CN102397558B
(zh)
|
2010-09-09 |
2013-08-14 |
中国人民解放军军事医学科学院毒物药物研究所 |
Exendin-4类似物的定位聚乙二醇化修饰物及其用途
|
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
|
EP3028720A1
(en)
|
2010-09-28 |
2016-06-08 |
Amylin Pharmaceuticals, LLC |
Engineered polypeptides having enhanced duration of action
|
|
ES2533601T3
(es)
|
2010-11-03 |
2015-04-13 |
Arecor Limited |
Nueva composición que comprende glucagón
|
|
CN103200940A
(zh)
|
2010-11-09 |
2013-07-10 |
曼金德公司 |
用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物
|
|
EP2460552A1
(en)
|
2010-12-06 |
2012-06-06 |
Sanofi-Aventis Deutschland GmbH |
Drug delivery device with locking arrangement for dose button
|
|
CN102552883B
(zh)
|
2010-12-09 |
2014-02-19 |
天津药物研究院 |
一种多肽复合物、药物组合物、其制备方法和应用
|
|
RS60321B1
(sr)
|
2010-12-16 |
2020-07-31 |
Novo Nordisk As |
Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline
|
|
JP2014504588A
(ja)
|
2010-12-22 |
2014-02-24 |
アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
膵島細胞移植のためのｇｌｐ−１受容体アゴニスト
|
|
KR20130132931A
(ko)
|
2010-12-22 |
2013-12-05 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
Gip 수용체 활성을 나타내는 글루카곤 유사체들
|
|
CN102532301B
(zh)
|
2010-12-31 |
2014-09-03 |
上海医药工业研究院 |
一类新型的Exendin-4类似物及其制备方法
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
CN102100906A
(zh)
|
2011-02-18 |
2011-06-22 |
深圳翰宇药业股份有限公司 |
一种艾塞那肽的药用制剂及其制备方法
|
|
EP2683364B1
(en)
|
2011-03-10 |
2017-01-18 |
Xeris Pharmaceuticals, Inc. |
Stable formulations for parenteral injection of peptide drugs
|
|
CN102718858B
(zh)
|
2011-03-29 |
2014-07-02 |
天津药物研究院 |
胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
|
|
CN106928341B
(zh)
|
2011-03-30 |
2021-06-01 |
上海仁会生物制药股份有限公司 |
定点单取代聚乙二醇化Exendin类似物及其制备方法
|
|
EP2694095B1
(en)
|
2011-04-05 |
2018-03-07 |
Longevity Biotech, Inc. |
Compositions comprising glucagon analogs and methods of making and using the same
|
|
US9480751B2
(en)
|
2011-04-11 |
2016-11-01 |
Yeda Research And Development Co. Ltd. |
Albumin binding probes and drug conjugates thereof
|
|
WO2012150503A2
(en)
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
|
CN102766204B
(zh)
|
2011-05-05 |
2014-10-15 |
天津药物研究院 |
胰高血糖素样肽-1突变体多肽及其制备方法和其应用
|
|
AU2012255119B2
(en)
|
2011-05-18 |
2017-04-20 |
Mederis Diabetes, Llc |
Improved peptide pharmaceuticals for insulin resistance
|
|
JP2014521594A
(ja)
|
2011-05-25 |
2014-08-28 |
アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
長持続期間デュアルホルモンコンジュゲート
|
|
UA113626C2
(xx)
|
2011-06-02 |
2017-02-27 |
|
Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
|
|
KR102002783B1
(ko)
|
2011-06-10 |
2019-07-24 |
베이징 한미 파마슈티컬 컴퍼니 리미티드 |
포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
|
|
DK3878859T5
(da)
|
2011-06-10 |
2024-06-10 |
Hanmi Science Co Ltd |
Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse
|
|
SI2721062T1
(sl)
|
2011-06-17 |
2019-03-29 |
Hanmi Science Co., Ltd. |
Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega
|
|
CN105797140B
(zh)
|
2011-06-17 |
2020-08-11 |
哈洛齐梅公司 |
乙酰透明质酸降解酶的稳定制剂
|
|
KR101972617B1
(ko)
|
2011-06-22 |
2019-04-25 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루카곤/glp-1 수용체 공동-항진제들
|
|
JP6184404B2
(ja)
|
2011-06-22 |
2017-08-23 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
グルカゴン／ｇｌｐ−１レセプターコアゴニスト
|
|
EP2723359A4
(en)
|
2011-06-24 |
2015-03-11 |
Amylin Pharmaceuticals Llc |
METHOD FOR THE TREATMENT OF DIABETES WITH THE HELP OF DELAYED RELEASED FORMULATIONS FROM GLP-1 RECEPTOR AGONISTS
|
|
KR101357117B1
(ko)
|
2011-06-28 |
2014-02-06 |
비앤엘델리팜 주식회사 |
폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
|
|
WO2013004983A1
(en)
|
2011-07-04 |
2013-01-10 |
Imperial Innovations Limited |
Novel compounds and their effects on feeding behaviour
|
|
EP2729481B1
(en)
|
2011-07-08 |
2018-10-17 |
Amylin Pharmaceuticals, LLC |
Engineered polypeptides having enhanced duration of action with reduced immunogenicity
|
|
DK2741765T3
(en)
|
2011-08-10 |
2016-06-13 |
Adocia |
Injectable solution of at least one type of basal insulin
|
|
EP4295858A1
(en)
|
2011-08-24 |
2023-12-27 |
ImmunoForge Co., Ltd. |
Formulations of active agents for sustained release
|
|
CN103189389B
(zh)
|
2011-09-03 |
2017-08-11 |
深圳市健元医药科技有限公司 |
新的glp‑ⅰ类似物及其制备方法和用途
|
|
AR088161A1
(es)
|
2011-09-23 |
2014-05-14 |
Novo Nordisk As |
Analogos de glucagon
|
|
BR112014010200A2
(pt)
|
2011-10-28 |
2020-10-27 |
Sanofi-Aventis Deutschland Gmbh |
combinação farmacêutica, bem como seu uso na preparação de um medicamento para o tratamento de diabetes tipo 2
|
|
CN102363633B
(zh)
|
2011-11-16 |
2013-11-20 |
天津拓飞生物科技有限公司 |
胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
|
|
BR112014007124A2
(pt)
|
2011-11-17 |
2017-06-13 |
Univ Indiana Res & Tech Corp |
superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
|
|
CN103998046B
(zh)
|
2011-11-29 |
2021-04-06 |
优奥斯私人有限公司 |
包含环糊精和疏水性药物的可注射药物组合物的防腐方法
|
|
HRP20220717T1
(hr)
|
2011-12-16 |
2022-07-22 |
Modernatx, Inc. |
Modificirani pripravci mrna
|
|
AU2012356219B2
(en)
|
2011-12-22 |
2016-03-31 |
Covx Technologies Ireland Limited |
Anti-diabetic compounds
|
|
SG11201403377QA
(en)
|
2011-12-23 |
2014-07-30 |
Zealand Pharma As |
Glucagon analogues
|
|
EP2797585A4
(en)
|
2011-12-29 |
2015-10-07 |
Latitude Pharmaceuticals Inc |
STABILIZED GLUCAGONNANOULULSIONS
|
|
BR112014016889A8
(pt)
|
2012-01-09 |
2017-07-04 |
Adocia |
composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
|
|
WO2013148871A1
(en)
|
2012-03-28 |
2013-10-03 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides
|
|
WO2013148966A1
(en)
|
2012-03-28 |
2013-10-03 |
Amylin Pharmaceuticals, Llc |
Transmucosal delivery of engineered polypeptides
|
|
WO2013151666A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
|
JP2015516143A
(ja)
|
2012-04-02 |
2015-06-08 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
|
|
CN102649947A
(zh)
|
2012-04-20 |
2012-08-29 |
无锡和邦生物科技有限公司 |
一种用于测定glp-1及其功能类似物生物活性的细胞株及其应用
|
|
EP2841090A1
(en)
|
2012-04-24 |
2015-03-04 |
Amylin Pharmaceuticals, LLC |
Site-specific enzymatic modification of exendins and analogs thereof
|
|
US20130289241A1
(en)
|
2012-04-26 |
2013-10-31 |
Shanghai Ambiopharm, Inc. |
Method for preparing exenatide
|
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
WO2013182217A1
(en)
|
2012-04-27 |
2013-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
JP6228187B2
(ja)
*
|
2012-05-03 |
2017-11-08 |
ジーランド ファーマ アクティーゼルスカブ |
Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
|
|
EP2844670B1
(en)
|
2012-05-03 |
2017-12-06 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (glp-2) analogues
|
|
EP2664374A1
(en)
|
2012-05-15 |
2013-11-20 |
F. Hoffmann-La Roche AG |
Lysin-glutamic acid dipeptide derivatives
|
|
CN103421094A
(zh)
|
2012-05-24 |
2013-12-04 |
上海医药工业研究院 |
一种具有epo类似活性的多肽化合物
|
|
US20150174209A1
(en)
|
2012-05-25 |
2015-06-25 |
Amylin Pharmaceuticals. Llc |
Insulin-pramlintide compositions and methods for making and using them
|
|
SG11201407860PA
(en)
|
2012-06-14 |
2014-12-30 |
Sanofi Sa |
Exendin-4 peptide analogues
|
|
ES2602486T3
(es)
|
2012-06-21 |
2017-02-21 |
Indiana University Research And Technology Corporation |
Análogos de glucagón que muestran actividad de receptor de GIP
|
|
CA2877127A1
(en)
|
2012-06-21 |
2013-12-27 |
Indiana University Research And Technology Corporation |
Analogs of glucagon exhibiting gip receptor activity
|
|
CA2878457C
(en)
|
2012-07-12 |
2021-01-19 |
Mannkind Corporation |
Dry powder drug delivery systems and methods
|
|
CA2878991C
(en)
|
2012-07-23 |
2021-12-07 |
Zealand Pharma A/S |
Glucagon analogues
|
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
|
AR094821A1
(es)
|
2012-07-25 |
2015-09-02 |
Hanmi Pharm Ind Co Ltd |
Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
|
|
WO2014027253A1
(en)
|
2012-08-14 |
2014-02-20 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
|
US20150258198A1
(en)
|
2012-08-14 |
2015-09-17 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
|
CN102816244A
(zh)
|
2012-08-23 |
2012-12-12 |
无锡和邦生物科技有限公司 |
一种Exendin-4肽与人血清白蛋白HSA的融合蛋白及其制备方法
|
|
CN102827270A
(zh)
|
2012-09-13 |
2012-12-19 |
无锡和邦生物科技有限公司 |
一种聚乙二醇化艾塞那肽衍生物及其用途
|
|
US9546205B2
(en)
|
2012-09-17 |
2017-01-17 |
Imperial Innovations Limited |
Peptide analogues of glucagon and GLP1
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
WO2014049610A2
(en)
|
2012-09-26 |
2014-04-03 |
Cadila Healthcare Limited |
Peptides as gip, glp-1 and glucagon receptors triple-agonist
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
MY168536A
(en)
|
2012-11-06 |
2018-11-12 |
Hanmi Pharm Ind Co Ltd |
Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin fc region
|
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
|
AU2013347975B2
(en)
|
2012-11-20 |
2018-07-26 |
Mederis Diabetes, Llc |
Improved peptide pharmaceuticals for insulin resistance
|
|
TWI674270B
(zh)
|
2012-12-11 |
2019-10-11 |
英商梅迪繆思有限公司 |
用於治療肥胖之升糖素與glp-1共促效劑
|
|
MX2015008114A
(es)
|
2012-12-21 |
2015-11-06 |
Sanofi Sa |
Derivados de exendina-4.
|
|
CN103908657A
(zh)
|
2012-12-31 |
2014-07-09 |
复旦大学附属华山医院 |
胰升糖素样肽-1类似物在制备眼科疾病药物中的用途
|
|
EP3238734A1
(en)
|
2013-03-14 |
2017-11-01 |
Medimmune Limited |
Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
|
|
WO2014158900A1
(en)
|
2013-03-14 |
2014-10-02 |
Indiana University Research And Technology Corporation |
Insulin-incretin conjugates
|
|
US20160058881A1
(en)
|
2013-03-15 |
2016-03-03 |
Indiana University Research And Technology Corporation |
Prodrugs with prolonged action
|
|
SI2986313T1
(sl)
|
2013-04-18 |
2019-09-30 |
Novo Nordisk A/S |
Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
|
|
JP2014227368A
(ja)
|
2013-05-21 |
2014-12-08 |
国立大学法人帯広畜産大学 |
糖尿病および高血糖状態の処置のためのグルカゴンアナログ
|
|
CN103304660B
(zh)
|
2013-07-12 |
2016-08-10 |
上海昂博生物技术有限公司 |
一种利拉鲁肽的合成方法
|
|
CN103405753B
(zh)
|
2013-08-13 |
2016-05-11 |
上海仁会生物制药股份有限公司 |
稳定的促胰岛素分泌肽水针药物组合物
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
PT3057984T
(pt)
|
2013-10-17 |
2018-10-24 |
Boehringer Ingelheim Int |
Análogos de glucagon acilados
|
|
JP2017503474A
(ja)
|
2013-11-06 |
2017-02-02 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
|
|
WO2015086729A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
EP3080151A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Exendin-4 peptide analogues
|
|
EP3080150B1
(en)
|
2013-12-13 |
2018-08-01 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
TW201609797A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
雙重ｇｌｐ－１／升糖素受體促效劑
|
|
EP3080155A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
|
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
CN103665148B
(zh)
|
2013-12-17 |
2016-05-11 |
中国药科大学 |
一种可口服给药的降糖多肽及其制法和用途
|
|
CN103980358B
(zh)
|
2014-01-03 |
2016-08-31 |
杭州阿诺生物医药科技股份有限公司 |
一种制备利拉鲁肽的方法
|
|
RU2016132342A
(ru)
|
2014-01-09 |
2018-02-14 |
Санофи |
Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
|
|
KR20160104726A
(ko)
|
2014-01-09 |
2016-09-05 |
사노피 |
인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
|
|
GB201404002D0
(en)
|
2014-03-06 |
2014-04-23 |
Imp Innovations Ltd |
Novel compounds
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
CN106519015B
(zh)
|
2014-09-23 |
2020-04-17 |
深圳市图微安创科技开发有限公司 |
胃泌酸调节素类似物
|
|
US9988430B2
(en)
|
2014-10-10 |
2018-06-05 |
Novo Nordisk A/S |
Stable GLP-1 based GLP-1/glucagon receptor co-agonists
|
|
EP3209682B1
(en)
|
2014-10-24 |
2020-12-30 |
Merck Sharp & Dohme Corp. |
Co-agonists of the glucagon and glp-1 receptors
|
|
WO2016198604A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
|
|
WO2016198624A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
|
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
|